Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals
Abstract
Purpose: Obesity raises metabolic and cardiovascular risk and represents a major public health challenge. The sodium-glucose cotransport-2 inhibitor empagliflozin (EMPA) may improve metabolic parameters beyond glycemic control. This systematic review critically evaluated the effects of EMPA on anthropometric and metabolic outcomes in overweight or obese subjects without diabetes and identified key areas for future research.
Methods: This systematic review included studies identified through searches of five databases (Scopus, Web of Science, PubMed, Google Scholar, and the Cochrane Library) from January 2023 to May 2026. Following duplicate removal and PRISMA-guided screening, 27 studies were included (7 randomized controlled trials and 20 animal studies). Studies were excluded if they involved diabetic populations, lacked appropriate comparator groups, or did not meet predefined eligibility criteria. The Cochrane and SYRCLE tools were used to assess the quality of human and animal evidence, respectively.
Results: Animal studies primarily used EMPA doses of 8-30 mg/kg/day, whereas human trials employed fixed clinical doses of 10-12.5 mg daily. In human investigations, EMPA significantly lowered body weight with notable improvements in fasting glucose. Preclinical studies largely supported these findings and additionally demonstrated improvements in hepatic steatosis, lipid metabolism, and inflammatory markers. Proposed mechanisms included modulation of FGF21 signaling,…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.